An open randomised trial of Zoladex versus CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less

Trial Profile

An open randomised trial of Zoladex versus CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2005

At a glance

  • Drugs Cyclophosphamide; Cyclophosphamide; Fluorouracil; Goserelin; Methotrexate
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZEBRA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 29 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top